telehealth.helpFind my match

Home WikiTelehealth Conditions

Type 2 diabetes

From WikiTelehealth, the telehealth.help reference · Last updated

Type 2 diabetes is a chronic disease in which the body does not respond well to insulin, so blood sugar stays too high. It makes up about 90% to 95% of all diabetes in the United States, where the CDC estimates 40.1 million people had diabetes in 2023.

Type 2 diabetes
TypeChronic metabolic disease
Share of diabetesAbout 90% to 95%
US people with diabetes40.1 million (2023)
US adults with prediabetes115.2 million (2023)
GLP-1 diabetes brandsOzempic, Rybelsus, Mounjaro, Trulicity, Victoza

Overview

Insulin is a hormone that moves sugar from the blood into cells for energy. In type 2 diabetes, cells stop responding well to insulin (insulin resistance), and over time the pancreas cannot make enough insulin to keep up. Blood sugar then rises. Over years, high blood sugar can damage the heart, blood vessels, kidneys, eyes and nerves.

Prevalence in the United States

The CDC estimates that 40.1 million people in the United States, or 12.0% of the population, had diagnosed or undiagnosed diabetes in 2023. Of these, 29.1 million had been diagnosed. About 11.0 million adults had diabetes but did not know it. Another 115.2 million adults had prediabetes, meaning blood sugar is higher than normal but not yet in the diabetes range.

Risk factors

The CDC lists several risk factors for type 2 diabetes. These include prediabetes, excess body weight, being 45 or older, a parent or sibling with type 2 diabetes, physical activity fewer than three times a week, and a history of diabetes during pregnancy. Type 2 diabetes is also more common in some racial and ethnic groups. Obesity is one of the strongest risk factors.

Use of GLP-1 medicines

GLP-1 medicines were first developed for type 2 diabetes. They help the pancreas release insulin when blood sugar is high, lower the release of glucagon, slow stomach emptying and reduce appetite. Most are used along with diet, exercise and often other diabetes medicines such as metformin.

Several GLP-1 brands are approved for type 2 diabetes rather than for weight loss. Ozempic (weekly semaglutide shot) was approved in 2017, Rybelsus (daily semaglutide tablet) in 2019 and Mounjaro (weekly tirzepatide shot) in 2022. The same molecules are sold under other names for weight management: Wegovy for semaglutide and Zepbound for tirzepatide. Older diabetes options in this class include liraglutide (Victoza) and dulaglutide (Trulicity). To compare these medicines side by side, see our GLP-1 medication comparison.

Compare GLP-1 medicines

See also

References

  1. CDC, National Diabetes Statistics Report. cdc.gov
  2. CDC, About type 2 diabetes. cdc.gov
  3. Drugs@FDA, Ozempic (NDA 209637). accessdata.fda.gov
  4. Drugs@FDA, Mounjaro (NDA 215866). accessdata.fda.gov

Last updated . Category: Conditions. Browse all 38 WikiTelehealth entries.